Gsa Capital Partners LLP Cel Sci Corp Transaction History

Gsa Capital Partners LLP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$1.63 - $3.08 $41,664 - $78,727	25,561 New	25,561 $48,000
Q2 2023 Aug 14, 2023	SELL	$2.11 - $2.83 $29,115 - $39,051	-13,799 Reduced 13.84%	85,904 $207,000
Q1 2023 May 12, 2023	BUY	$2.17 - $3.13 $216,355 - $312,070	99,703 New	99,703 $231,000
Q2 2022 Aug 09, 2022	BUY	$2.58 - $4.99 $393,388 - $760,855	152,476 Added 914.29%	169,153 $761,000
Q1 2022 May 11, 2022	SELL	$3.93 - $7.7 $356,042 - $697,589	-90,596 Reduced 84.45%	16,677 $66,000
Q4 2021 Feb 14, 2022	SELL	$7.1 - $12.82 $6,823 - $12,320	-961 Reduced 0.89%	107,273 $762,000
Q3 2021 Nov 12, 2021	BUY	$7.64 - $12.49 $734,104 - $1.2 Million	96,087 Added 791.03%	108,234 $1.19 Million
Q2 2021 Aug 05, 2021	BUY	$8.68 - $27.49 $105,435 - $333,921	12,147 New	12,147 $105,000
Q1 2021 May 10, 2021	SELL	$12.0 - $27.64 $272,688 - $628,091	-22,724 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$11.05 - $16.62 $251,100 - $377,672	22,724 New	22,724 $265,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.